This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=93 http://www.lsis.com/goto/r93/rss 2012-02-05T11:10:59+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 Background:? We investigated the proarrhythmic potential of terfenadine in isolated rabbit hearts, left ventricular wedge preparations, and the effects on the human ether-a-go-go related gene (HERG) current in a human embryonic kidney cell line (HEK293) with a stable transfection of hERG and on I(Na) current not only in rabbit ventricular cells but also in human atrial myocytes. Methods and Results:? By means of the whole-cell patch-clamp recording, terfenadine concentration- and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 Background and purpose.? JNJ-26070109 is a novel CCK(2) receptor antagonist with good pharmacokinetic properties and represents a novel mechanism for the treatment of gastro-oesophageal reflux disease (GORD). The purpose of the present study was to determine whether chronic treatment with JNJ-26070109 could prevent as well as treat acid rebound in rats. Experimental approach.? A chronic fistula was surgically inserted into the stomach of rats to enable the measurement of acid secretion (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 Johnson & Johnson hid studies showing its Risperdal anti-psychotic drug caused diabetes to protect billions of dollars in sales, a lawyer said in the first personal-injury claim over the medication to go to trial. Researchers at J&J s Janssen unit knew as early as 1999 that a study found Risperdal caused diabetes at a higher rate than a competing drug and failed to hand over the results to regulators probing links between the disease and anti-psychotic medicines, Fletch Trammell, a lawyer for (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 5-Hydroxytryptamine (5-HT) receptors, by virtue of their broad expression pattern in peripheral and central tissues, regulate diverse physiological and behavioral responses through the activation of fourteen molecularly distinct receptor subtypes. The tissue-specific distribution of these receptors confers specificity for the actions of serotonin and highlights the therapeutic potential of serotonin receptor modulators. To better assess this therapeutic potential, it is useful to characterize (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 Determining the in vivo bactericidal potential of novel agents is critical for selecting drug candidates. Described in this unit are two protocols that measure the amount of bacterial killing under very different conditions. The mouse pouch protocol is a rapid assay that provides efficacy data in an acute infection, whereas the rabbit tissue cage protocol assesses the ability of a compound to eradicate bacteria in a chronic abscess infection. Data from these tests, along with those from other (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 CONFERENCE PROCEEDING Proceedings of the PDA/FDA Adventitious Viruses in Biologics: Detection and Mitigation Strategies Workshop in Bethesda, MD, USA; December 1-3, 2010 Guest Editors: Arifa Khan (Bethesda, MD), Patricia Hughes (Bethesda, MD) and Michael Wiebe (San Francisco, CA) Approaches to viral safety issues for biological products have evolved during the past 50+ years. The first cell culture products (viral vaccines) relied largely on the use of in vitro and in vivo virus screening (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 A Johnson & Johnson prostate-cancer medicine discovered in England and developed with funds from U.K. charities is too expensive for the country s National Health Service. The NHS shouldn t pay for Zytiga because the drug s benefits don t justify the cost even after the manufacturer agreed to cut the price, the National Institute for Health and Clinical Excellence said in a statement today. The agency, known as NICE, advises the state-run medical system on which treatments it should pay for. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 To provide mechanistic insight in the induction of phospholipidosis and the appearance of the proposed biomarker di-docosahexaenoyl (C22:6)-bis(monoacylglycerol) phosphate (BMP), rats were treated with 150 mg/kg amiodarone for 12 consecutive days and analyzed at three different time points (day 4, 9, and 12). Biochemical analysis of the serum revealed a significant increase in cholesterol and phospholipids at the three time points. Bio-analysis on the serum and urine detected a time-dependent (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 Background and Purpose:? JNJ-Q2, a novel broad spectrum fluoroquinolone with anti-MRSA activity, was evaluated in a comprehensive set of nonclinical and clinical cardiovascular safety studies. The effect of JNJ-Q2 on different cardiovascular parameters was compared to that of moxifloxacin, sparfloxacin and ofloxacin. Through comparisons to these well-known fluoroquinolones, the importance that compensatory ion channel effects have on the cardiovascular safety of JNJ-Q2 was investigated. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 February 01, 2012 - Global medical device players, Johnson & Johnson and Medtronic, are re-organising their Asia Pacific operations and transitioning back to more global business models. This effectively reduces the strategic management layer at the Asia Pacific level. Some say this could be to a) improve communications directly globally and/or b) reduce costs as having additional regional structures cuts into profits. Both Johnson & Johnson and Medtronic have been moving significant (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 Sustained release formulations of a potent antithrombotic drug, cilostazol, in poly-(lactic acid-co-glycolic acid) (PLGA) matrices were created for luminal release from a novel drug-eluting stent utilizing reservoirs (RES TECHNOLOGY?). The crystallinity of cilostazol and the morphology of the cilostazol/polymer matrix in the stent reservoirs were examined by cross-polarized optical microscopy and differential scanning calorimetry. An in vitro method was developed to study release kinetics of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 Johnson & Johnson is shaking up oversight of the troubled unit that makes Tylenol and other over-the-counter medicines once again, naming new leadership less than a year after manufacturing problems sparked a revamp. The New Brunswick, N.J., health-products giant is replacing two company group chairmen who held key roles trying to turn around a consumer business racked by recalls and more than $1 billion in lost sales of popular cold, pain and allergy medicines. Patrick Mutchler, who was put (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 RUTHERFORD, Calif.-(BUSINESS WIRE)-The International Mental Health Research Organization (IMHRO) has announced its 2012 IMHRO Rising Star Translational Research Awards, which are sponsored by IMHRO and Johnson & Johnson Services, Inc. IMHRO and the Corporate Office of Science and Technology of Johnson & Johnson Services, Inc. identify and fund critical and cutting edge research on the causes of and cures for brain disorders. IMHRO serves as an umbrella organization to provide support for (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 New York, New York (PRWEB) January 30, 2012 - Bernstein Liebhard LLP reports that health regulators in Britain are concerned that recipients of the metal-on-metal DePuy ASR hip implants were never notified that the devices were recalled.* In August 2010, DePuy Orthopaedics, a subsidiary of Johnson & Johnson, issued a voluntary worldwide recall of its ASR hip implant systems, after receiving data from the National Joint Registry of England and Wales that 1 out of every 8 patients (12%-13%) who (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=93 United States Patent: 8106094 |-| Title: Compositions and methods for treating skin conditions |-| Inventors: Sah; Archana (Redmond, WA), Dole; Victoria (Whitehouse Station, NJ), Nystrand; Glenn (Lebanon, NJ), Seiberg; Miri (Princeton, NJ), Liu; Jue-Chen (Belle Mead, NJ), Kurtz; Ellen (Ringoes, NJ) |-| Assignee: Johnson & Johnson Consumer Companies, Inc. (Skillman, NJ) |-| This invention relates to methods and compositions for treating and ameliorating skin conditions including post (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 The rates of oxidative degradation of a new antibacterial drug, RWJ416457, in aqueous solutions were investigated over the pH-range of 2 to 10. Two oxidative degradates were identified and the influences of pH, buffer concentration, metal ions, metal chelating agents, and temperatures were studied. The pH, metal chelating agents, and metal ions significantly changed the product distribution in addition to the degradation rate. Oxidative degradation is believed to follow a hydrogen abstraction (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 ? Adaptation of skin barrier function and interleukin-1? (IL-1?) content in diapered and nondiapered skin are poorly characterized in newborns receiving standard skin care. In a monocentric, prospective pilot study 44 healthy, full-term neonates were randomly assigned to skin care with baby wipes (n?=?21) or water-moistened washcloth (n?=?23) at each diaper change. Transepidermal water loss (TEWL), skin hydration, skin-pH, IL-1?, and epidermal desquamation were measured on days 2, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 Background and purpose.? The aim of this study was to characterize the functional impact of KCNQ1-encoded voltage-dependent potassium channels (K(v) 7.1) in the vasculature. Experimental approach.? Mesenteric arteries, intrapulmonary arteries and thoracic aortae were isolated from adult rats. K(v) 7.1 channel expression was established by fluorescence immunocytochemistry. Wire myography determined functionality of these channels in response to selective blockers and activators. Xenopus (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 Pfizer Inc. and Bristol-Myers Squibb Co. s blood-thinner apixaban won a final recommendation from the U.K. s health-cost agency. The pill, also known by the brand name Eliquis, may be used to prevent blood clots in adults who have undergone hip or knee replacement surgery, the National Institute for Health and Clinical Excellence said in a statement today. The agency, known as NICE, advises the state-run National Health Service on which treatments represent value for money. Almost 120,000 hip (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 The McNeil Consumer Healthcare plant in Fort Washington, Montgomery County, will not resume production until at least 2013, Johnson & Johnson's chief executive officer, Bill Weldon, said Tuesday as the company reported 2011 full-year and fourth-quarter financial results. Recalls, repairs, litigation, and costs related to the acquisition of Synthes Inc. played a big part in J&J's profit dropping 88.8 percent in the fourth quarter of 2011 compared with the same period a year earlier. Companies (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 NASHVILLE, Tenn.-(BUSINESS WIRE)-Kathryn E. Barnett of the national plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that Paul McCurley of Chattanooga, Tennessee, has filed a lawsuit against DePuy Orthopaedics, Inc., and its parent company, Johnson & Johnson, Inc., for the injuries he suffered after his DePuy Pinnacle metal on metal hip implant failed. The lawsuit charges that DePuy knew that the Pinnacle metal on metal hip generated unusual and dangerous levels of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 DUBLIN-(BUSINESS WIRE)- Covidien plc (NYSE: COV - News) today announced that its Board of Directors has elected President and Chief Executive Officer José E. Almeida to the additional position of Chairman of the Board, effective March 13, 2012. Mr. Almeida will succeed Richard J. Meelia, who has served as Chairman since October 2008. Mr. Meelia agreed to serve as Non-Executive Chairman of the Board for a transition period of up to one year following his July 2011 retirement as President (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 Johnson & Johnson said on Thursday it will pay $158 million to settle a Texas lawsuit accusing the drugmaker of improperly marketing its Risperdal anti-psychotic drug to state residents on the Medicaid health program for the poor. The settlement fully resolves all Risperdal-related claims in Texas, the company said. The agreement is specific to the state of Texas and does not involve other ongoing state or federal Risperdal litigation. The deal settles claims brought by Texas in 2004 and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 SAN DIEGO-(BUSINESS WIRE)- La Jolla Pharmaceutical Company (OTCBB: LJPC.PK - News) (the œCompany  and œLa Jolla ) today announced that it has acquired global development and commercialization rights to GCS-100, a novel therapeutic, from privately held Solana Therapeutics, Inc. ( œSolana ). GCS-100 is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in cancer and chronic organ failure. In connection with the acquisition, George F. Tidmarsh, M.D., Ph.D., (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 Chichester, UK (PRWEB) January 9, 2012 According to a new Espicom report, Evolution in the Pain Therapy Market: Nociceptive and Neuropathic Drug Development, despite a plethora of medications, the pain market remains an area of high unmet need as current therapies are often less than effective and/or have undesirable side effects. Among the challenges facing the pharmaceutical industry is the rapid rise in prescription drug abuse, particularly in the US, where it has reached epidemic (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 19 January 2012 - Oxford Innovation has been appointed by the Welsh Government to deliver a new programme that will assist start-up and early stage life sciences firms with high growth potential to grow more rapidly over the next three years. The High Potential Starts programme is a key component of the Welsh Government s strategy to support sustainable high growth businesses. The programme is jointly funded by the Welsh Government and the European Regional Development Fund. The programme (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 Johnson & Johnson officials hid three studies showing some patients using Risperdal developed diabetes while claiming the antipsychotic drug didn t cause the disease, a witness testified. As early as 1999, Johnson & Johnson s Janssen unit had researchers findings that about half the patients taking Risperdal in a study comparing its risks to those of Eli Lilly & Co. s Zyprexa antipsychotic drug developed diabetes after a year on the medication, Joseph Glenmullen, a psychiatrist and Harvard (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 Johnson & Johnson subsidiary Depuy Orthopaedics decides to stop selling all custom devices following an FDA letter warning the company to file new PMA and 510(k) applications for several components. Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Orthopaedics decided to stop selling all custom fitted devices in response to an FDA warning following an inspection of the Warsaw, Ind.-based company's facilities. This week the FDA's Centers for Devices & Radiological Health released a letter warning (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 OBJECTIVE: To determine the efficacy of various cleaning and disinfective methods in reducing bacterial and fungal load on flexible fiberoptic laryngoscopes (FFLs). DESIGN: In vitro model. SUBJECTS: Flexible fiberoptic laryngoscopes contaminated with Staphylococcus aureus and Candida albicans. INTERVENTIONS: Contamination with S aureus and C albicans was separately induced on FFLs, which were then disinfected with different protocols: 20-, 15-, 10-, and 5-minute soaks in (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 Johnson & Johnson s West Coast research leader, Diego Miralles, has met with a lot of biotech entrepreneurs who are curious about what J&J is doing to foster more startups at its facility in San Diego. At some point, a skeptical question usually comes up. œWhat s the catch?  Miralles says he s sometimes asked. He insists there isn t any catch. œWe are genuinely trying to help the industry,  Miralles said last week in a meeting at the JP Morgan Healthcare Conference in San Francisco. œWe (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 U.S. regulators haggling with medical-device makers over how much it will cost to speed up product reviews starting this year missed a legal deadline to submit a proposal for congressional approval. Under a 2007 law, the companies, led by Johnson & Johnson and Medtronic Inc., were charged $295 million over five years to get products such as hip implants and heart stents reviewed in a timely manner. The law, set to be reauthorized this year, mandates that the agency submit a new agreement to (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 Drug-induced liver injury (DILI) is a major cause of attrition during both the early and later stages of the drug development and marketing process. Reducing or eliminating drug-induced severe liver injury, especially those that lead to liver transplants or death, would be tremendously beneficial for patients. Therefore, developing new pharmaceuticals that have the highest margins and attributes of hepatic safety would be a great accomplishment. Given the current low productivity of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 The antipsychotic drug Risperdal was marketed for children and adolescents by Johnson & Johnson s Janssen unit after warnings by the U.S. Food and Drug Administration not to do so, a witness told jurors. Janssen s marketing to children began after the drug s introduction in 1994 and continued until the FDA s first approval for pediatric uses in 2006, jurors in state court in Austin, Texas, heard yesterday from attorney Arnold Friede, an expert witness for the state. Texas seeks at least $579 (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 Second City Communications and Corpedia Release Funny and Engaging Video Called œCompany Retreating  Exploring Boundaries and Privacy When Using Social Media At The Office œCompany Retreating  is One of Many Timely, Relevant Videos on Ethics and Compliance Topics Served Up In the Innovative Video Library Called RealBiz Shorts CHICAGO-(BUSINESS WIRE)- Just because the boss can connect with employees through online social networks, is it a good idea? And if managers do connect to (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=93 United States Patent: 8097715 |-| Title: Multitargeting interfering RNAs having two active strands and methods for their design and use |-| Inventors: Rivory; Laurent Pierre (New South Wales, AU), Poidinger; Michael (New South Wales, AU), Birkett; Donald John (New South Wales, AU), Arndt; Gregory Martin (New South Wales, AU), Passioura; Toby (New South Wales, AU) |-| Assignee: Johnson & Johnson Research PTY Limited (Eveleigh, NSW, AU) |-| Interfering RNA molecules are now designed and produced (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 DIAMOND BAR, Calif.-(BUSINESS WIRE)- Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the FDA approval of the new THERMOCOOL SF irrigated ablation catheter in the United States. The THERMOCOOL SF NAV Catheter combines Biosense Webster s latest irrigated ablation technology with the accurate visualization of the CARTO3 3D Mapping & Ablation System. The catheter was launched in Europe in October, 2010 and has received excellent (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 Drug maker Cilag in the canton of Schaffhausen says it will shed 120 jobs. Cilag has about 1,100 employees but it says it plans to drop a large part of its active ingredient production by 2015. The pharmaceutical company said increasing price pressure has driven it to look at products with higher margins and growth potential. Cilag is a subsidiary of U.S. giant Johnson & Johnson and is a major employer in Schaffhausen. The company said it hoped most of the job cuts would come through natural (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 Johnson & Johnson s Animas unit kept selling insulin pumps last year after learning of malfunctions with the devices that prompted it to make design changes, the Food and Drug Administration said. The agency faulted the J&J unit for not adequately explaining œwhy your firm continued to manufacture insulin pumps  after they œhad known failures.  The issues with Animas One Touch Ping and 2020 pumps prompted a company investigation that started in April, according to the FDA s letter, which (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 On the heels of Quebec's worst three-month jobs losses in a generation, Johnson & Johnson says it is closing its research centre in the province. New Jersey-based J&J, the world's biggest health care products company, told employees at its Montreal research and development centre Tuesday morning that the facility would shut down in March. Some 126 people work at the centre, including 36 J&J employees and 90 from a private placement agency hired on a contract basis, said the company's Quebec (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 Minneapolis / St. Paul Business Journal by Ed Stych, Web Producer Medtronic Inc. has lost the president of its international operations, as Jean-Luc Butel has taken a similar position with competitor Baxter International Inc. Butel, 55, will report to Baxter CEO Robert Parkinson Jr. and will start his new job as president of international operations on Feb. 20, according to a Baxter news release. Parkinson said in a statement that Butel's international experience will help Deerfield, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 Aims: Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that is being investigated for the treatment of type 2 diabetes mellitus (T2DM). Methods: This was a randomized, double-blind, placebo-controlled, parallel-group, 28-day study conducted at 2 sites, in 29 subjects with T2DM not optimally controlled on insulin and up to 1 oral antihyperglycemic agent. Subjects were treated with canagliflozin 100 mg QD or 300 mg BID or placebo. Safety, tolerability, pharmacokinetic (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 January 10, 2012 - Norwich, a leader in full-service contract development and manufacturing, is expanding its services to now include small scale feasibility and initial product development for prescription and over-the-counter pharmaceuticals. The non-GMP development facility will offer Norwich customers greater flexibility and speed when assessing the feasibility of technical concepts and formulations, and create streamlined progression from clinical into scale-up and through commercial (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 London, 10 January 2012 - Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has announced that the Technology Strategy Board has funded a research consortium comprising of Plasticell, Pfizer (Neusentis) and the University of Sheffield, led by Cellzome. The project will develop methods of characterizing stem cells through protein fingerprints predictive of changes in stem cell behaviour. The Technology Strategy Board will (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 January 10, 2012 - Norwich, a leader in full-service contract development and manufacturing, is expanding its services to now include small scale feasibility and initial product development for prescription and over-the-counter pharmaceuticals. The non-GMP development facility will offer Norwich customers greater flexibility and speed when assessing the feasibility of technical concepts and formulations, and create streamlined progression from clinical into scale-up and through commercial (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 Boehringer Ingelheim GmbH s anti- coagulant Pradaxa increases a patient s risk of heart attack or severe chest pain, according to a review of studies conducted on the drug. An analysis of seven clinical trials found that it was œsignificantly associated with a higher risk  of heart attacks and acute coronary syndrome, or ACS, a designation that includes heart attacks and chest pain, researchers wrote in a report published today in the Archives of Internal Medicine. The potential risk of (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=93 United States Patent: 8093293 |-| Title: Methods for treating skin conditions |-| Inventors: Seiberg; Miri (Princeton, NJ), Liu; Jue-Chen (Belle Mead, NJ), Iotsova; Violetta (Robbinsville, NJ) |-| Assignee: Johnson & Johnson Consumer Companies, Inc. (Skillman, NJ) |-| This invention relates to methods and compositions for treating and ameliorating skin conditions including acne, rosacea and wrinkling caused by photodamage or intrinsic aging. More particularly, this invention relates to (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=93 United States Patent: 8093448 |-| Title: Absorbent article including absorbent core having a plurality of first regions and a second region surrounding each of the first regions |-| Inventors: De Carvalho; Antonio Carlos Ribeiro (Taubate, BR), Fajolli; Marcia Helena Teixeira (Sao Jose dos Campos, BR), Salles; Maria Marcia R. Caldas (Sao Jose dos Campos, BR) |-| Assignee: Johnson & Johnson Ind. E. Com LTDA (BR) |-| An absorbent article including a absorbent core having a plurality of first (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 CHICAGO, Illinois, January 9, 2012 - Only 10% of molecules that enter Phase II will reach market, according to recent analysis by the Pharmaceutical Benchmarking Forum (PBF). And that is on top of growing attrition rates in earlier phases for preclinical and initial human studies that make the overall challenge of bringing drugs through Development even greater. This analysis is based on very detailed data from the PBF - which consists of the leading pharmaceutical companies - and offers the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=93 Background:? Irreversible electroporation (IRE) is a largely non-thermal method for the ablation of solid tumours. The ability of ultrasound (US) to measure the size of the IRE ablation zone was studied in a porcine liver model. Methods:? Three normal pig livers were treated in vivo with a total of 22 ablations using IRE. Ultrasound was used within minutes after ablation and just prior to liver harvest at either 6?h or 24?h after the procedure. The area of cellular necrosis was (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=93 Johnson & Johnson will pay more than $1 billion in civil and criminal penalties to the federal government and individual states to settle an investigation into the marketing practices of its anti-psychotic drug Risperdal, Bloomberg News Service reported Thursday. The figure would be in line with what Eli Lilly & Co. paid three years ago to settle claims that it marketed a similar anti-psychotic drug, Zyprexa, for illnesses that weren t approved by the U.S. Food and Drug Administration. œThese (…)